A federal judge in Tennessee has declined to certify two classes in an antitrust case accusing a subsidiary of Pfizer Inc. of conspiring to keep cheaper generic versions of its Skelaxin muscle relaxant off the market. In Thursday’s 67-page decision, U.S. District Judge Curtis Collier in Chattanooga found the cases brought on behalf of end payers and indirect purchasers of the drug were inappropriate for class treatment.
Kaye Scholer represents Pfizer’s King Pharmaceuticals unit in the litigation and Munger, Tolles & Olson represents codefendant Mutual Pharmaceuticals.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]